Diary - News
All news Imaxio strengthens its intellectual property
Imaxio strengthens the intellectual property of its vaccines pipeline with two new patents granted in the United States. They offer Imaxio additional cover on the American market for the new generation of its antigen re-engineering technology, and for its influenza vaccine candidate.
By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree